STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

CJC-1295 / Ipamorelin (blend discussion)

Also known as

CJC Ipamorelin · CJC/IPA · CJC-1295 no DAC + Ipamorelin · CJC IPA blend · Mod GRF 1-29 + Ipamorelin · CJC-1295/Ipamorelin · CJC + Ipa · CJC1295 Ipamorelin stack · GHRH + GHS blend (CJC/IPA) · CJC no DAC / IPA · Mod GRF + Ipamorelin · CJC IPA 5/5 · CJC-1295 Ipam

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Lots of talk Systemic SubQ Growth hormone axis

Systemic — a GHRH analog plus a ghrelin-receptor agonist, discussed for whole-body sleep, recovery and composition rather than local tissue repair.

What people say This is a community pairing of short-acting CJC-1295 without DAC/Mod GRF 1-29 and Ipamorelin. Premixed labels are often ambiguous, and true DAC CJC is a different active moiety with multi-day kinetics. Doses people talk about
Separate equal-pair chartAbout 100 mcg no-DAC CJC plus 100 mcg Ipamorelin per administration

A common 100/100 community entry, not a validated first-use amount.

Separate paired bandsAbout 100–200 mcg no-DAC CJC plus 100–300 mcg Ipamorelin per administration

Common paired ranges, with some CJC charts extending to 300 mcg; not a dose-equivalence rule.

Ipamorelin-heavy pairAbout 100 mcg no-DAC CJC plus 200–300 mcg Ipamorelin per administration

Community chart pattern possible with separate products; a fixed 1:1 premix cannot represent it.

Equal mid-band chart200 mcg plus 200 mcg per administration

Coach-template amount sometimes paired with five-days-on/two-days-off or equal on/off blocks.

Premixed 1:1 chartsAbout 200–500 mcg total blend per administration

If the stated fill is truly 1:1, the total divides between components; vendor ratio and fill accuracy remain uncertain.

Community frequency talk spans once nightly, twice daily, or two to three times daily, often tied to fasting and sleep narratives. These are reports, not an escalation path; human IV Ipamorelin monotherapy did not validate the SubQ blend schedules.

Half-life & effect duration

Half-life in the body
  • No-DAC CJC / Mod GRF · community estimateAbout 30 minutes
  • Other community guidesAbout 1–2 hours
  • Ipamorelin · IV studyAbout 2 hours
  • Other reported IV estimatesAbout 2.4–3.1 hours at lower studied doses
Felt duration people report
  • After one missed nightWorse sleep in some accounts
  • After two off nightsGood sleep or vivid dreams persisted in other accounts
  • During continued useSleep benefit or daytime sleepiness by week 3
Timing context & sources
How it may feel Sleep and vivid dreams are the most repeated early reports, but users also describe no effect, daytime sleepiness, fluid retention, flushing, anxiety, increased heart rate or chest pain; one separate account described hives and swelling on a later cycle. Recovery claims emerge over weeks and are heavily confounded.
Cycles people discuss Legacy discussion includes 8–12-week blocks, five-days-on/two-days-off patterns and lab-timed reassessment. These are community calendars, not schedules validated by the cited IV Ipamorelin study. Timing Bedtime and morning-plus-bedtime use both appear in no-DAC/Ipamorelin discussion. Some reports describe administration roughly 2–3 hours after the last meal, then another 20–60 minutes before eating; hunger makes that routine contentious. These are community rules, not validated food windows or a schedule for CJC with DAC. Stacks The CJC/Ipamorelin pairing is itself the core stack. MK-677 and repair peptides are additional community contexts that add appetite, glucose, fluid and attribution confounders. Access talk Three shelves people mix: leftover 503A clinic fills (pharmacy-dependent), wellness pens/cartridges, and RUO 5/5 or 10/10 vials. “Peptides are legal again” 2026 headlines were not a CJC/IPA bulks-list add. Labs people mention IGF-1 is the proxy people actually pull — baseline, then ~weeks 4–8, same lab if they can. Pulsatile no-DAC + IPA is widely said to move trough IGF-1 less than DAC or IU-dosed somatropin. Watch for Glucose / insulin sensitivity: GH elevation can worsen insulin resistance; community and clinic notes sometimes advise fasting glucose/HbA1c awareness, especially with MK-677, surplus calories, or prediabetes.
Related
IpamorelinSermorelinTesamorelinGHRP-2GHRP-6

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

The reviewed evidence does not establish a human half-life for CJC-1295 without DAC/Mod GRF 1-29.

The approximately 30-minute figure is widespread in community charts, but FDA's review found no human study of the CJC-1295 free-base or acetate active moieties; published human studies likely involved DAC.

No-DAC labeling is inconsistent in commerce, and DAC measurements cannot be transferred to a distinct active moiety.

Half-life in the body

Ipamorelin had an approximately two-hour terminal half-life after intravenous infusion in healthy men.

Forty-eight healthy men were enrolled across five escalating-dose groups; active participants received a 15-minute IV infusion. GH peaked around 0.67 hours and was very low by six hours.

Intravenous monotherapy, unspecified product form, small per-dose groups and healthy men; this is not SubQ or premixed-blend pharmacokinetics.

Felt duration people report

Reports after one or two omitted nights conflict, so no dependable sleep-effect carryover can be assigned.

Some users reported severe sleep disruption after one missed nightly administration, while others said vivid dreams or good sleep persisted through two off nights after several weeks. Separate threads report both sleep benefit and daytime sleepiness by week three.

Self-reports, unverified products, mixed ratios, different prior exposure and no objective sleep record; omitted-night experience is not residual-peptide measurement.

  • Sleep issues after skipping a single dose of CJC-1295/Ipamorelin (opens in a new tab)Post body reports sleeping one to two hours after one missed evening. Replies include another missed-dose sleep problem and same-author follow-ups saying vivid dreams or good sleep persisted through two off nights after about six weeks.Different authors, ratios and products; attribution to one missed dose is speculative, and the thread contains no objective sleep-stage or peptide-level measurements.
  • Increased sleepiness and vivid dreams on Ipamorelin/CJC-1295 (opens in a new tab)Post body at week three: 200 mcg Ipamorelin plus 150 mcg CJC no-DAC on a five-days-on/two-days-off bedtime pattern, followed by daytime sleepiness, lost motivation and vivid dreams.Single unverified self-report, paired products, no laboratory or sleep measures and no same-author resolution located.
  • Personal experiences with CJC-1295 and Ipamorelin (opens in a new tab)Replies include a week-three bedtime account with deep sleep, vivid dreams, water/bloat and strength/recovery changes, plus separate reports of no benefit and strong sleep benefit. The OP later described increased heart rate, anxiety, chest pain, flushing and racing sensations that seemed milder over the following week; another commenter described hives, swelling, redness and a rapid heartbeat on a third cycle.Multiple authors, products, ratios, cycles and co-treatments; product identity and reaction descriptions lack medical confirmation, and the contradictory anecdotes do not establish incidence, causality or a single effect clock.

What people say 17

  • Sleep (fastest / most consistent claim): Deeper sleep, easier fall-asleep, and vivid dreams often reported within ~1–2 weeks — the dominant early anecdote for bedtime empty-stomach dosing. Clinic marketing timelines often list sleep in week 1–2. forum
  • Recovery / readiness: Less next-day soreness and faster multi-session training readiness over several weeks in multi-month logs — heavily confounded by sleep, calories, and concurrent TRT/AAS. forum
  • Body composition: Fat-loss edge and lean-mass support talk becomes common by months 2–3+; diet, training, water retention, and co-stacks often co-credited. Not framed as a rapid cut drug. forum
  • Joints / soft tissue: Some report easier connective-tissue comfort under load — weaker and less consistent than sleep reports. anecdote
  • Fullness / skin: Mild GH-like fullness, skin turgor, or “look” notes; extracellular water can mimic “fullness.” forum
  • Energy (secondary): Mild daytime energy lift sometimes reported after sleep improves — not a stimulant “buzz.” forum
  • Vs older GHRPs: Preferred over GHRP-6/2 for less extreme hunger and less cortisol/prolactin side-effect talk while still providing a GHS pulse. forumanimal
  • Synergy claim: GHRH + GHS receptors framed as a larger coordinated pulse than either alone — core bro rationale for always stacking rather than running IPA monotherapy. Some advanced posters argue IPA alone at community microdoses is near-noise without a GHRH partner. forum
  • IGF-1 as proxy: Some track serum IGF-1 to confirm the axis was engaged; rise is typically milder/pulsatile with no-DAC multi-pulse protocols than with high-dose with-DAC or pharmacologic rGH. Non-responders on labs often recheck product identity before blaming “genetics.” forumtrial
  • Vs rGH expectation: Users often describe softer results than 2–4+ IU/day somatropin but fewer classic high-dose GH sides at community secretagogue doses — cost and legality also drive the choice. forum
  • Muscle preservation talk (GLP-1 era): Discussed next to tirzepatide/semaglutide cuts as recovery/lean-mass support — confounded by protein, resistance training, and calorie deficit severity. forum
  • Contest / prep adjacency: Used in prep and recomp phases for sleep/recovery when users want GH-axis support without full rGH protocols. forum
  • Vs Tesamorelin (anecdote split): Some logs call CJC/IPA better for “building/recovery/sleep,” Tesamorelin better for visceral-fat focus (Tesa has an approved HIV-lipodystrophy fat indication — not the same as blend bodycomp RCTs). forumtrial
  • Vs Sermorelin + IPA: Same GHRH+GHS logic; CJC/Mod GRF is the forum default, sermorelin more clinic-branded; head-to-head lifestyle superiority is not trial-proven. forum
  • 2025–26 sleep still first: X and Reddit logs still treat deeper sleep / vivid dreams in week 1–2 as the “it landed” marker on a bedtime empty-stomach pin — physique talk stays months-scale. forum
  • Fasted vs night argument: A loud 2025 PeptideForum split: if dinner was late, a truly fasted morning pin is called cleaner than forcing a fed bedtime shot onto the nocturnal pulse. forum
  • Sleep-science adjacent (not blend RCTs): Broader GHRH literature is cited for slow-wave sleep interest; that is not the same as a CJC/IPA blend RCT. trial

Doses people talk about 20

  • Common starter (separate peptides): ~100 mcg CJC-1295 no DAC + ~100 mcg Ipamorelin per injection — the classic “100/100” that saturates beginner charts. forum
  • Per-peptide bands when paired: No-DAC CJC commonly ~100–200 mcg per shot (some charts allow up to ~300 mcg); Ipamorelin commonly ~100–300 mcg per shot. Many prefer IPA equal to or higher than CJC. forum
  • Saturation-dose lore (Mod GRF / no-DAC CJC): Forum lore often treats ~100 mcg (sometimes framed as ~1 mcg/kg) as near-max useful pulse for the GHRH analog — pushing CJC far above that is widely called waste while flushing/headache risk rises; the strategy is add GHS (IPA), not double GHRH. Critics note this 100 mcg “clinical saturation” claim is not from a published no-DAC human dose-finding trial. forum
  • IPA saturation debate: Older bro charts also slapped ~100 mcg as IPA “saturation.” Advanced threads push back using volunteer PK/PD context (Gobburu et al. 1999 dose-escalation; very low bands near noise) and argue IPA’s practical community range sits higher (~200–300+ mcg) especially when paired with GHRH — or that IPA monotherapy at microdoses underperforms. Practice still clusters 100–300 mcg per pin in lifestyle protocols. forumtrial
  • Popular “optimized” split (IPA-heavy): Charts and logs often land around 100 mcg CJC no DAC + 200–300 mcg Ipamorelin per injection rather than strict 1:1 forever — separate vials enable this; premix 1:1 locks it. forum
  • Equal mid-band: 200/200 mcg per injection appears in coach templates (sometimes with 5 on / 2 off and equal on/off blocks). forum
  • Upper multi-pulse talk: Advanced charts discuss 100–200 mcg CJC + 200–300 mcg IPA per injection, 2–3×/day — total daily peptide load rises fast (can approach ~0.6–1.5+ mg combined/day depending on math); sides, cost, and pin fatigue scale with it. forum
  • Frequency spectrum: 1× bedtime only (beginner / sleep / lifestyle); 2× (AM fasted + night); or 2–3× pulse (AM / post-workout / pre-bed) on empty stomach. Bedtime dose is consistently called the most important for sleep goals. forum
  • Other clinic starting talk: Some marketing cites ~0.2 mg per injection as a typical starting total-blend figure; still provider-dependent. forum
  • With-DAC is a different drug schedule: Community/research DAC talk is often ~1–2 mg/week total (or historical trial mcg/kg bands ~30–60+ mcg/kg in Teichman healthy adults), not daily 100 mcg co-injection with IPA. Do not plug DAC into a no-DAC blend chart. forumtrial
  • Empty-stomach rule (very strong culture): Inject fasted or wait ~30–60+ minutes after food (many say ≥1–2 hours, especially after carbs/fats), then delay food ~20–60 minutes post-shot so insulin does not blunt the GH pulse. Clinic pages often hard-require ≥2 h after last meal for bedtime dose. forum
  • Separate vials vs premix: Separate vials let you run IPA-heavy ratios, verify each peptide, and isolate which component failed if results are flat; premix is convenience but locks ratio and hides underfill of one peptide. forum
  • Titration culture: Many guides start low (100/100 or low clinic units) and increase every 1–2 weeks only if sleep/sides allow — not jump straight to 3×/day high band. forum
  • 2025–26 extra camps (not one ladder): Bedtime-only 100/100 or IPA-heavy 100/200–300; AM fasted + night; 2–3×/day 100/100; 5-on/2-off. 2025 Reddit still fights 100 mcg CJC “saturation” vs IPA 200–300. forum
  • Skip-the-fed-night camp: If they cannot wait ~2–3 hours after dinner, 2025–26 advice in those threads is skip tonight and pin morning fasted rather than “stack it on a full stomach.” forum
  • Units ≠ mcg: Copying “4 units = 100/100” from someone else’s BAC volume is the 2026 calculator-thread failure mode. Premix 1:1 also cannot do the IPA-heavy split separate vials allow. forum
  • Reddit-style titration examples (anecdotal logs): Start 100/100 ×1–2/day → step IPA to 150 with CJC 100 → some advanced logs go 100 CJC + 200 IPA morning and night, or add a third post-workout pulse. Individual logs are not protocols. anecdote
  • Premixed 1:1 vials (research-chem charts): Often labeled e.g. 5 mg CJC + 5 mg IPA (10 mg total) or 10/10. Common chart doses: ~200–500 mcg total blend per injection (e.g. 300 mcg blend ≈ ~150/150 if truly 1:1; 200 mcg blend ≈ 100/100). Standard vendor tables often cite 300–500 mcg total blend, 2–3× daily. Ratios and fill accuracy vary by vendor. forum
  • Blend reconstitution math (talk, not a mix chart): 5 mg/5 mg (10 mg total) vs 10/10 labels are still mixed up. A “200 mcg” pin may mean 200 mcg total (~100/100 on a true 1:1) or 200 mcg of each (~400 mcg total). Water volume only changes syringe *units*, not milligrams in the vial. forum
  • Framing: Community, clinic-marketing, and research-chem chart ranges only — not prescriptions, not FDA-labeled dosing for this blend, not validated athletic protocols. forum

How it may feel 12

  • Night of first doses: Little daytime “buzz”; bedtime drowsiness, warmer sleep, or vivid dreams are the usual first signals when dosed pre-bed fasted. forum
  • Nights 1–7: Sleep/dream changes dominate; mild facial flush 10–20 minutes post-shot can appear; physique unchanged. forum
  • Weeks 1–2: Sleep anecdotes peak; early hand/face puffiness or ring tightness can start (GH/fluid path); clinic charts often list energy mild lift in this window if sleep improved. forum
  • Weeks 6–8: Body-comp and skin/fullness talk becomes more common; still lifestyle-heavy; first “is this worth the pin cost?” checkpoint. forum
  • Months 2–3: “Baseline recovery better” and composition anecdotes in longer logs; plateau talk starts if dose/schedule never changed; common lab reassess window (IGF-1, fasting glucose). forum
  • Clinic marketing timeline (not trial): Sleep ~1–2 weeks → energy ~2–4 weeks → body composition ~6–12 weeks appears in wellness protocol pages — treat as marketing cadence, not controlled outcome data. forum
  • After stop: Sleep often drifts toward baseline in days–weeks; body-comp tracks training/diet more than an acute “crash.” No classic AAS-style PCT narrative for this stack alone. anecdote
  • Fed-night restless camp (2025–26): Logs that pin inside ~2 hours of food (even juice, kombucha, honey tea) describe being hot, restless, or “wired in bed” instead of sleepy. They blame insulin/food, not the mcg count. forum
  • Sleep-tracker minority: Some 2025 wearable logs show *less* deep sleep after a 250/250 bedtime pin and call it histamine / too-late food / too-high GHRH — not a universal “always sleeps harder” story. anecdote
  • GLP-1 delayed-emptying camp: 2026 reta/sema threads say the night fasted window becomes a coin flip, so they move the dual pin to first-thing morning, 30+ min before food. Sleep credit may drop. forum
  • Flat-lab feel: 2026 “100/100 × 6 weeks, IGF-1 barely moved, no flush” posts are common; the thread then argues underdosed vs pulsatile no-DAC not lifting trough IGF-1 vs fake vial — not a single answer. forum
  • Month 3+ / multi-month: Many stay on with scheduled offs (e.g. 8–12 on / ~4 off or 3-on/1-off clinic templates); continuous year-round use is less carefully logged and has thinner safety framing. forum

Around the dose 8

  • Clock: Night, empty stomach, then sleep — the named dual is a bedtime stack in most charts. forum
  • Training: Lift in the day. This combo is not a pre-workout. forum
  • Hunger: Ipamorelin hunger vs “don’t eat after the pin” is the nightly argument. forum
  • After: Sleep quality is what people credit when the combo “felt like recovery.” forum
  • Empty-stomach night pin (still the default lore, 2025–26): Last calories ~2–3 hours before the shot, then sleep — carbs/insulin near the pin are still blamed for a blunted GH pulse. Water is usually allowed; juice/honey/kombucha often is not. forum
  • Split vs bedtime: Bedtime-only for sleep; AM fasted + night when they want a second pulse. 3×/day dies on the fasted-window calendar. DAC weekly is a different product — don’t copy this blend’s nightly habit onto DAC. forum
  • After the pin: Community rule is don’t eat for ~20–60 minutes. Ipamorelin hunger vs that rule is the nightly argument. forum
  • GLP-1 overlap: Delayed gastric emptying can fake a “fasted” night. 2026 logs move the pin to morning rather than guess. forum

Cycles people discuss 12

  • Common research-chem on-block: ~8–12 weeks on for no-DAC daily or multi-daily protocols, then ~4 weeks off is a widely repeated template (receptor rest / cost / lab recheck rationale). forum
  • Longer clinic-style template: ~3 months on / ~1 month off appears in wellness marketing for ongoing “optimization” (sometimes framed as three cycles per year). forum
  • Alternate clinic off length: Some clinic pages describe 1–3 months on followed by 2–3 months off (longer washout than research-chem 4-week offs). forum
  • 5 days on / 2 days off: Very common weekly pattern (weekdays on, weekends off) aimed at cost control and theoretical receptor rest; superiority vs daily continuous is anecdotal. forum
  • 8 on / 8 off (variant): Some coaches publish equal on/off blocks (e.g. 200 mcg each daily, 5/2 within the on phase) — one of several unvalidated schedules, not a standard of care. forum
  • Pulse micro-schedules (minority): Occasional “4 days on / 3 days off” style pulse blocks appear in forum archives alongside other GHS schedules — not dominant for this blend. forum
  • Why off periods (stated reasons): Desensitization concerns, cost, lab rechecks (IGF-1/glucose), testing whether sleep/recovery hold without the blend, and reducing cumulative GH-axis exposure. forum
  • Re-runs: Common around contest prep, injury seasons, age-related wellness goals, stacked TRT blocks, or post-GLP-1 recomp phases. forum
  • Restart dose culture: Some clinic narratives say first cycle escalates units; later cycles return straight to prior maintenance — still provider-specific marketing, not a trial finding. forum
  • Continuous long-term: Some clinic patients stay on for many months with provider follow-up; long-horizon safety of gray-market multi-year multi-daily use is not established like approved GH products under endocrine care. forum
  • No dedicated PCT for the blend alone: Unlike AAS, community does not run SERM PCT “for CJC/IPA only”; stack PCT follows any concurrent suppressives. forum
  • 2026 lab-gated blocks: Baseline IGF-1 + fasting glucose, recheck around weeks 4–8, then decide 8–12 on / ~4 off vs keep bedtime-only. Flat IGF-1 is treated as a product/timing question before a mcg jump. forum

Timing 12

  • CJC-1295 no DAC / Mod GRF 1-29: ~30 minutes is a widely repeated community estimate (some guides stretch it to ~1–2 hours), not a measured human half-life. FDA found no human study of CJC-1295 free base or acetate; DAC kinetics cannot be transferred to this form. forumtrial
  • Pulsatility note (DAC literature): Ionescu & Frohman 2006-era work is often cited that episodic GH pulses can persist even with long-acting CJC-1295 stimulation (not pure flat “GH bleed only”) — bro media still prefers no-DAC + IPA when the goal is sharp, timed pulses with GHS. trialforum
  • Bedtime preferred: Aligns with nocturnal GH physiology and the sleep-improvement anecdotes that dominate user reports; largest natural pulse is early deep sleep. forum
  • AM / PWO pulses: Extra daytime pulses used when chasing recovery/body-comp; still require fasted windows — practical friction is the main limiter for 3×/day. forum
  • Insulin / food interaction (practice rule): Carbohydrate/insulin near the shot is treated as a GH-pulse blunter; timing discipline is considered as important as mcg count. forum
  • IGF-1 lag: Acute GH pulse is hours-scale; composition/tissue talk is framed as weeks of repeated pulses + training, not next-morning magic. forum
  • Pulsatile vs “GH bleed” debate: No-DAC + IPA is sold as preserving peaks/valleys; with-DAC is criticized in bro media for filling valleys / more continuous elevation — physiology arguments cite general continuous-vs-pulsatile GH literature; head-to-head lifestyle RCTs of blend vs DAC are not the evidence base. forumtrial
  • After last dose: IPA and no-DAC clear on the order of hours; subjective sleep benefit may linger a few nights from habit/recovery, not residual peptide depot. forum
  • Ipamorelin PK (human IV volunteers): Gobburu et al. 1999 used 15-minute intravenous infusions in healthy men: terminal half-life ~2 hours, clearance ~0.078 L/h/kg, Vss ~0.22 L/kg; GH peaked around 0.67 h and fell to very low levels by 6 h. These are not subcutaneous-blend kinetics. trial
  • Ipamorelin half-life nuance: Some secondary summaries cite elimination half-life bands ~2.4–3.1 h at lower studied doses and longer apparent values at higher dose levels in older PK writeups — still short-acting relative to DAC CJC or oral MK-677. trial
  • CJC-1295 with DAC (contrast only): Teichman et al. JCEM 2006 — estimated half-life ~5.8–8.1 days; single subq doses produced dose-dependent mean GH increases ~2- to 10-fold lasting ≥~6 days and mean IGF-I increases ~1.5- to 3-fold lasting ~9–11 days; multiple dosing kept mean IGF-I above baseline up to ~28 days. Particularly well tolerated at studied 30 or 60 μg/kg bands in that healthy-adult work. trial
  • DAC trial dose context (not blend dosing): Teichman single-dose arms included roughly 30, 60, 125, and 250 μg/kg groups with dose-related Cmax/AUC — this is not 100/100 no-DAC + IPA. trial

More on what it is 11

  • What it is: Community default stack of short-acting CJC-1295 (no DAC / Mod GRF 1-29) + Ipamorelin, almost always as subcutaneous injectables — either drawn into one syringe from separate vials or sold as a premixed research-chem/clinic vial. forum
  • Two pathways (“amplifier + trigger”): CJC/Mod GRF hits the GHRH receptor and amplifies/extends each GH pulse; Ipamorelin hits GHS-R1a (ghrelin receptor) and triggers a clean release pulse. Forums treat co-timing both as the reason the pair “works better than either alone.” forum
  • Why blend culture won: One shot (often bedtime, fasted) instead of running either solo; highest-volume dual secretagogue pairing across Reddit peptide forums, BB GH threads, Discord research-chem culture, and telehealth/compounding marketing. forum
  • No-DAC preferred for blends: Blend culture wants short, natural-ish pulses co-timed with Ipamorelin. With-DAC is a multi-day sustained GH/IGF-1 profile (weekly-style dosing) and is usually not what people mean when they say “CJC/IPA blend.” forumtrial
  • Naming trap: “CJC-1295” on a blend label almost always means no DAC / Mod GRF 1-29 in research-chem charts. True CJC-1295 with DAC (albumin-binding Drug Affinity Complex) is a different schedule and should not be plugged into daily 100/100 charts. forumtrial
  • Selectivity lore (why IPA beat GHRP-2/6): Animal characterization (Raun et al. 1998) framed Ipamorelin as releasing GH without meaningful ACTH/cortisol elevation even at very high multiples of the GH ED50 — vs GHRP-2/6 which raise cortisol/ACTH. That is why IPA locked the GHS slot in modern blends. animalforum
  • Evidence honesty (critical): Human PK/PD exists for each agent separately (especially CJC-with-DAC Teichman 2006 and Ipamorelin volunteer PK/PD + post-op ileus Phase II). The blend-as-sold for wellness/body-comp lacks robust RCTs. Community guides openly note Mod GRF / no-DAC has sparse dedicated human dose-finding. Most “results” are forum/clinic anecdote + GH-axis theory. trialforum
  • RUO after clinic squeeze: 2025–26 threads treat “research use only / not for human consumption” vials as the leftover shelf when a 503A shop won’t fill CJC/IPA. Same names, none of the pharmacy identity. forum
  • Not rGH / not a steroid: Does not inject recombinant somatropin; does not suppress the HPG axis like AAS; not FDA-approved for bodybuilding, fat loss, sleep, or anti-aging. trial
  • Research-only framing: Gray-market and compounded products are not interchangeable with approved GH products under endocrine care; purity, fill weight, and DAC vs no-DAC labeling remain practical failure modes. forum
  • 2026 access mix-up: April 2026 Category-2 removals and the July 23–24 2026 PCAC seven were BPC / TB-500 / KPV-class headlines. CJC + ipamorelin were already off 503A Category 2 after 2024 nomination withdrawals and were not on that July vote. trial

Stacks 14

  • Core stack: CJC (no DAC) + Ipamorelin is the stack — many never run either solo after starting the pair. forum
  • MK-677 (Ibutamoren): Compared or stacked for oral 24h GH-axis coverage + sleep; adds appetite, water, and fasting-glucose confound. Some prefer inject-only secretagogues during cuts; others run low-dose MK with bedtime CJC/IPA. Redundant GHS load is a common caution. forum
  • Repair peptides (“Wolverine”): BPC-157 and/or TB-500 in injury-season recovery logs alongside GH-axis support — different mechanism (local repair talk vs systemic GH pulse). forum
  • GLOW / copper-adjacent recovery stacks: GHK-Cu sometimes layered in wellness “repair + GH axis” narratives; ratios and evidence quality vary widely. forum
  • TRT / men’s health context: Frequently layered on testosterone replacement in clinic and forum logs — sleep/recovery complement, not a testosterone replacement. forum
  • GHRH swaps: Sermorelin or tesamorelin may replace CJC as the GHRH leg; Ipamorelin often stays as the GHS leg (Sermorelin+IPA and Tesa+IPA are named alternatives). forum
  • Tesamorelin add-on debate: Some stack Tesa with CJC/IPA for “general GH + visceral fat” — others call dual GHRH redundant/expensive; lab monitoring talk rises with multi-GHRH exposure. forum
  • vs recombinant GH: Stack used as a “milder alternative,” bridge, or budget path; high-end physique still often chooses rGH when budget/risk tolerance allows. Low-dose rGH + secretagogue talk exists but multiplies cost/side complexity. forum
  • GLP-1 era: Discussed for lean-mass/recovery support during tirzepatide/semaglutide cuts — evidence is lifestyle anecdote; watch protein intake and resistance training first. forum
  • Avoid redundant GHS overload: Stacking IPA + GHRP-2/6 + MK-677 simultaneously multiplies hunger/water/glucose noise with unclear extra benefit. forum
  • Avoid DAC + daily IPA “set and forget” confusion: Running weekly DAC CJC while still pinning IPA daily is a different protocol from no-DAC co-injection; some do it, but timing/rationale differs and water/glucose talk can rise with sustained IGF-1. forum
  • NAD+ / off-cycle wellness (clinic marketing): Some clinics pitch NAD+ or other adjuncts during peptide off-blocks — marketing adjacency, not blend synergy data. forum
  • Insulin sensitizer talk (advanced): Metformin/berberine-type discussions appear when GH-axis use coincides with rising fasting glucose — individual medical decisions, not a stack recipe. forum
  • 2026 reta/tirz adjacency: Lean-preservation talk next to GLP-1 cuts is louder; the practical fight is the fasted window, not a new mcg chart. forum

Access talk 6

  • Three shelves people mix: leftover 503A clinic fills (pharmacy-dependent), wellness pens/cartridges, and RUO 5/5 or 10/10 vials. “Peptides are legal again” 2026 headlines were not a CJC/IPA bulks-list add. forum
  • Prescription vs gray: A compounded fill is not a research-chem COA. DAC vs no-DAC mislabel on blend vials is still the identity trap. forum
  • Not on the July 2026 PCAC seven. That vote was BPC-157, KPV, TB-500, MOTS-c, emideltide/DSIP, Semax, Epitalon — not this blend. trial
  • 503A path is the 2024 leftover: Nominations for CJC-1295 and ipamorelin were withdrawn (FDA notice Sept 20, 2024; off Category 2 ~Sept 27, 2024). October 2024 PCAC voted against adding ipamorelin to the 503A bulks list; December 4, 2024 PCAC voted against CJC-1295-related bulk substances (FDA minutes: 0 yes / 13 no on the free-base question). Neither is on the 503A bulks list. trial
  • Ipamorelin acetate still 503B Category 2 on FDA’s safety-risk page (content current 22 Apr 2026) — immunogenicity / unnatural-amino-acid characterization talk, plus the IV postoperative-ileus literature FDA cites for serious events including death. That is not a gym-subq clearance. trial
  • CJC-1295 withdrawn-nomination note: FDA still lists increased heart rate and systemic vasodilatory reaction among identified serious events; clinical data remain limited. trial

Labs people mention 5

  • IGF-1 is the proxy people actually pull — baseline, then ~weeks 4–8, same lab if they can. Pulsatile no-DAC + IPA is widely said to move trough IGF-1 less than DAC or IU-dosed somatropin. forum
  • Modest/flat IGF-1 on 100/100 bedtime is a 2026 thread genre. Interpretations: expected for once-nightly no-DAC, underdosed vs IPA-heavy/multi-pulse charts, timing/food, or underfilled vial — not a diagnosis. forum
  • Some 2026 protocol sheets name a ~200–300 ng/mL IGF-1 “sweet spot” and warn against chasing past ~400 — forum/clinic lore, not an FDA range and not age-adjusted. Age-matched reference + z-score talk is the careful version. forum
  • Glucose watch: fasting glucose ± fasting insulin/HOMA-IR and A1c on longer or stacked runs (especially + MK-677 or GLP-1). GH-axis water can coexist with a “fine” IGF-1. forum
  • Draw timing talk: morning, often fasted; some skip the night pin so the draw is not an acute pulse. IGF-1 is the usual marker; random GH is too spiky. forum

Storage notes 3

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
  • Blend math trap (still not a mix SOP): People argue 1 mL vs 2 mL vs 3 mL bacteriostatic water only because it changes how many insulin-syringe *units* equal 100/100. This card still does not publish a reconstitution chart — labels and fill weights differ. forum

Watch for 22

  • Injection site: Redness, itch, sting, warmth, or mild swelling — worse with daily multi-pin use and poor site rotation. Most common practical complaint. forum
  • Flushing: Transient facial warmth/flush shortly after the shot (often ~10–20 minutes) is a classic acute effect, more noted when GHRH dose is pushed. forum
  • Water retention: Mild edema, ring tightness, hand/face puffiness, or early bloating — especially weeks 1–4; GH/IGF-1-linked sodium/water retention. Usually milder than high-dose rGH lore at secretagogue doses. forum
  • Headache / lightheadedness: Headache or dizziness reported by some, usually transient; hydration and dose adjustment are common first responses. forum
  • Tingling / carpal-like: Finger numbness or carpal-tunnel-like symptoms appear in higher-GH-axis anecdotes (fluid around median nerve narrative); wellness checklists flag this as a stop/reassess / dose-cut signal. forum
  • Appetite: Can still raise hunger despite “cleaner than GHRP-6” marketing — usually milder than GHRP-6 lore but not always zero. forum
  • Nausea: Occasional queasiness after injection in clinic side-effect lists. forum
  • Dreams / grogginess: Intense dreams or morning lethargy some users dislike (especially bedtime dose); others treat vivid dreams as a “it worked” marker. anecdote
  • Fatigue / drowsiness post-injection: Some feel ready-to-sleep after the pin — another reason bedtime dosing is preferred. forum
  • Joint stiffness / aches: Occasional joint discomfort or stiffness as GH-axis exposure rises — dose/frequency review in community guidance. forum
  • Glucose / insulin sensitivity: GH elevation can worsen insulin resistance; community and clinic notes sometimes advise fasting glucose/HbA1c awareness, especially with MK-677, surplus calories, or prediabetes. forumtrial
  • Cortisol/prolactin (relative claim): Raun et al. 1998 animal/swine work — Ipamorelin did not raise ACTH/cortisol like GHRP-2/6 even at >200× GH ED50; none of tested GHS raised FSH/LH/PRL/TSH in that profiling. Bro culture extrapolates “cleanest GHS,” but individual human responses still vary — not a free pass. animalforum
  • Cancer / proliferation caution: Active malignancy or significant cancer history is a common clinic absolute/relative avoid list item for GH-axis agents (theoretical growth-signal / IGF-1 concern) — not blend-specific trial proof of causality. forum
  • Pregnancy / nursing: Standard research and clinic materials flag avoid — not studied as a lifestyle secretagogue stack in pregnancy. forum
  • Source / legal risk: Gray-market purity, underfilled vials, DAC/no-DAC mislabel, research-only legal status, compounding variability, and sparse formal interaction data remain major practical cautions. forum
  • Not risk-free: Dual research peptides ≠ safe OTC sleep aid; long-term unsupervised multi-daily use lacks the monitoring framework of approved GH products. forum
  • CJC trial history note: Published healthy-adult DAC studies (Teichman 2006 JCEM; related pulsatility work) inform half-life/IGF-1 expectations for with-DAC, not automatic safety clearance for daily no-DAC + IPA research-chem protocols. No-DAC / Mod GRF human dose-finding is sparse relative to forum confidence. trialforum
  • When community says stop/reassess: Progressive hand numbness, significant edema, rising fasting glucose, severe headaches, or suspected product reaction — drop dose/frequency and seek medical care rather than “push through.” forum
  • Water / carpal / glucose (2025–26 GH-axis triad): Ring tightness, hand tingling, and fasting-glucose creep are still what people watch on multi-pulse or stacked runs — dose-cut / off-week talk, not a “push through” story. forum
  • 2026 compounding leftover risk: After 503A shops refused CJC/IPA, displaced demand talk moved to RUO powder. Underfill and DAC/no-DAC swaps stay the practical failure mode. forum
  • Ipamorelin clinical history note: Human data includes PK/PD volunteer work (Gobburu 1999) and Phase II postoperative-ileus programs (e.g. NCT00672074; published Beck et al. proof-of-concept — not effective enough for POI approval path). Development did not yield an approved body-comp/anti-aging indication. Do not confuse “studied in humans” with “approved stack for physique.” trial
  • WADA / tested athletes: GH secretagogues and related releasing factors are prohibited in sport — not a “natural loophole.” trial

Updated: 2026-09-01

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →